Main Article Content
Cardiac amyloidosis is considered a rare disease and classically described as having poor prognosis, with a median survival of six months, since the onset of heart failure symptoms. When cardiac amyloidosis is suspected, the etiological study is indicated for characterization of the type of protein involved, as well evaluation of the attainment of other organs. In this article, the authors report two cases, diagnosed and treated at Hospital CUF Descobertas (HCD) - in cooperation with Instituto Português de Oncologia de Lisboa (IPOL) and National Amyloidosis Centre (NAC) in London - of heart failure in the context of AL amyloidosis associated with monoclonal gammopathy.
The patients maintain regular follow-up in HCD and are clinically well.
Received: 02/05/2017 - Accepted: 18/08/2017